Mesthelioma or malignant Mesthelioma is a type of cancer. It develops a lining that covers many of the body's internal organs. Mostly on the lungs or internal chest wall.But it doesn't mean that it cant be on the other body parts it can also be in the abdominal cavity.
It means the likely outcome of an illness, or you can say that percentage of people that will survive or die.
There are three types of mesothelioma.
"Pro diagnosis" is the term used by doctors to report the likely outcome of a disease, how long a diagnosed patient is expected to live, and the quality of life time expected in the coursework of that. Diffuse malignant mesothelioma is an very aggressive disease, and the prognosis is very poor, both for pleural mesothelioma (development related) and peritoneal mesothelioma (abdominal), as well as pericardial mesothelioma (heart related). Median survival time of 6 to 18 months after diagnosis is reported.
Mesothelioma is classified in to five types, based on the type of cells involved: epithelial (50% of cases), sarcomatoid (15% of cases), and mixed type (35% of cases) (1). Epithelial mesothelioma has a better survival rate than the sarcomatoid or mixed types. Mesothelioma is also classified based on site of original involvement. The pleural (development) type is most common. About 80% of cases are pleural in origin (2). Mesothelioma peritoneal (abdominal) is much more rare.
Mesothelioma diagnosis prognosis for plenty of cancers depends on how early the disease is diagnosed and treatment is begun. One of the main issues in diagnosing mesothelioma is that the first signs can be very vague. Patients may at first visit their doctors with signs of shortness of breath or chest pain. These signs can be present with a sizable number of other conditions and by the time other diseases and conditions are ruled out, the mesothelioma may have advanced far, since it develops very quickly. Sometimes mesothelioma develops without signs at first, and the first sign could be a pleural effusion (liquid around the lungs) that is incidentally noticed on a chest x-ray of completed for other reasons. The mesothelioma gets a jumpstart before it is ever diagnosed, making the prognosis all the more extreme.
Following a diagnosis of pleural mesothelioma, chest pain and shortness of breath often grow worse, sometimes followed by weight loss, night sweats, and anorexia. The tumor gradually obliterates the pleural space and replaces any pleural liquid. The development becomes encased and is not free to move. The development can be covered in a thick rind of tumor of 5 cm or more. Operating to remove this degree of tumor encasement may be of very high risk to the patient, or impossible. Deoxygenated blood is shunted through the development, which ends up in fatigue and low oxygen levels that may not be improved by supplemental oxygen. There may be invasion of the chest wall and nearby structures measured by tumor which may cause increasing pain and other abnormalities such as difficulty of swallowing, compression of the superior vena cava, vocal cord or diaphragm paralysis.
Development Metastases can occur to the other, the brain or other sites, though this is unusual. A way more common issue is extension to the abdominal cavity. This can be at issue for patients who have had a lovely response to early aggressive therapy for pleural disease; with the increased survival time comes increased chance of spread to the abdominal cavity.
Death usually occurs from infection or respiratory failure than as a direct result of metastatic disease. Extension to the abdomen may cause death by bowel obstruction. Invasion of heart or pericardium may cause death from arrhythmia, heart failure or stroke.
Diffuse malignant peritoneal mesothelioma (DMPM), the more rare type that begins in the abdomen, has overall survival rates averaging one year. Most of these are epithelioid types. There's reports of a more "indolent" type of DMPM which progresses slowly and can have significantly longer survival rates, measured in years than months. A major predictor of survival rate in DMPM is the depth of invasion of the bowel wall, with cases of only superficial invasion having an extended survival rate. Surgical resection of affected bowel in these cases may improve life expectancy.
Doctors look at a set of indicators when determining prognosis for any disease condition. In cases of mesothelioma there's several known factors that are associated with better prognosis or worse prognosis.
Mesothelioma life expectancy indicators of a better prognosis and thus longer life expectancy and higher quality of life include: earlier stage epithelial type of mesothelioma, age under 65 years at diagnosis, absence of chest pain, lovely performance status (a measurement of cancer patient well-being based on factors such as ability to work, look after self, etc.), and presence of signs for over five months before diagnosis. This last factor may indicate a more "indolent" or less aggressive type of mesothelioma.
Indicators of a poor prognosis include: higher stage presence of high platelet counts in the blood (thrombocytosis), elevated white blood cell count, fever of unknown origin, sarcomatoid or mixed type of mesothelioma, age 65 or older at diagnosis, male, and poor performance status.
Most often, treatment for mesothelioma is "palliative," meaning it is based on easing the signs, as there's limited cures with poor survival rates. Radiation therapy can help with reducing the spread of tumor tissue (metastases). Ongoing clinical trials use a combination of radiation, chemotherapy and surgical procedure to increase survival rate the poor.
Mesothelioma treatment clinical trials however, experimental treatments such as gene therapy and immunotherapy offer hope for longer survival. Emerging therapies follow a multimodality approach, attacking the disease with surgical procedure, chemotherapy and radiation therapy, and there's trends proposing greater survival rates. Aggressive surgical procedure may involve removal of pleura, lung, diaphragm and pericardium. This treatment aims to remove as much tumor tissue as feasible while leaving normal lung tissue intact. There's some preliminary statistics that recommend that combining such aggressive surgical procedure with radiation and chemotherapy, for a sure subset of more youthful, healthier patients, may greatly improve life expectancy and perhaps cure.
Sometimes it can be helpful to look at specific numbers than sizable scale statistical studies. At the Dana-Farber Institute in Boston, doctors followed case histories of 120 patients with pleural mesothelioma from 1980 to 1995. All these patients were treated with surgical procedure and a combination of chemotherapy and radiation therapy. Some received immunotherapy. Of patients with sarcomatoid or mixed type mesothelioma, 20% were alive 2 years later. All had died within 5 years. Patients with epithelioid type had a much better outlook. Those with no involvement of lymph nodes showed a 74% survival rate after 2 years and survived 39% after 5 years (6). Newer therapies will probably push these survival numbers higher as better combinations of treatments are proved in clinical trials.
Though very rare, there's long term survivors of mesothelioma with greater than 10 years post diagnosis. Researchers speculate that survival rates in these cases may have more to do with individual differences among patients than the categories of therapy they receive
